| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates","as_of":"2026-04-22T13:12:40.941923+00:00","canonical_url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates","article_chars":4061,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_66467f05b0549dd3","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-22T13:19:42.121572+00:00","extraction_method":"trafilatura","fetched_description":"Elevance Health (ELV) delivered earnings and revenue surprises of 6.78% and 5.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?","fetched_title":"Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates | Nasdaq","final_url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates","source_event_id":"evt_216ecd0bc442","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"4916822508fb0896","kind":"new_listings","published_at":"2026-04-22T11:15:01+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["March 2026","quarter ended March 2026","quarter ended March 2025","May 1"],"entities":[{"asset_class":"equity","name":"Elevance Health, Inc.","relevance":"high","symbol":"ELV","type":"company"},{"asset_class":"other","name":"Zacks Consensus Estimate","relevance":"high","symbol":"","type":"estimate_benchmark"},{"asset_class":"index","name":"S&P 500","relevance":"medium","symbol":"^GSPC","type":"market_index"},{"asset_class":"equity","name":"Organon","relevance":"low","symbol":"OGN","type":"company"}],"event_type":"earnings","information_gaps":["The article text provided does not explicitly state ELV\u2019s reported revenue figure for the quarter ended March 2026; it only provides a revenue surprise percentage (+3.68%) and separate consensus revenue figures for the coming quarter and current fiscal year.","The article\u2019s stated earnings surprise of 6.78% conflicts with the source summary\u2019s stated +17.74% (unclear whether +17.74% refers to revenue or another metric).","The signal type guidance mentions discovery_new_listings_delta, but the provided text is about earnings; no new listing details are present in the excerpt.","No specific management commentary content is included; only that it will be important for near-term stock movement."],"key_facts":["ELV quarterly earnings were $11.97 per share versus a Zacks Consensus Estimate of $11.21 per share (beating by $0.76).","The article states an earnings surprise of 6.78% for the quarter ended March 2026.","The article states revenue surprise of +3.68% (exact revenue figure is not explicitly tied to the surprise in the provided text, but the coming-quarter consensus revenue is given as $47.67B).","ELV earnings were $10.64 per share a year ago (adjusted for non-recurring items).","Over the last four quarters, ELV surpassed consensus EPS estimates three times.","The article states ELV shares have added about 10.2% since the beginning of the year, while the S&P 500 declined -12.3%.","Ahead of the earnings release, the estimate revisions trend was described as mixed, resulting in a Zacks Rank #3 (Hold).","The article gives a current consensus EPS estimate of $9.81 and consensus revenues of $47.67 billion for the coming quarter.","The article gives a current consensus EPS estimate of $34.19 and consensus revenues of $192.23 billion for the current fiscal year.","The article states the Zacks Industry Rank for Medical Services is currently in the bottom 42% of 250+ Zacks industries.","The article mentions Organon (OGN) has yet to report results for the quarter ended March 2025, expected May 1, with expected quarterly earnings of $0.92 per share and consensus EPS revised 1.7% lower over the last 30 days."],"numeric_claims":[{"label":"ELV EPS (reported, adjusted)","value":"$11.97 per share"},{"label":"ELV EPS (Zacks consensus)","value":"$11.21 per share"},{"label":"Earnings surprise","value":"6.78%"},{"label":"Earnings surprise (stated in source summary)","value":"+17.74%"},{"label":"Revenue surprise (stated in source summary)","value":"+3.68%"},{"label":"ELV EPS (year ago, adjusted)","value":"$10.64 per share"},{"label":"ELV YTD share performance","value":"+10.2%"},{"label":"S&P 500 YTD performance","value":"-12.3%"},{"label":"Zacks Rank","value":"#3 (Hold)"},{"label":"Consensus EPS (coming quarter)","value":"$9.81"},{"label":"Consensus revenues (coming quarter)","value":"$47.67 billion"},{"label":"Consensus EPS (current fiscal year)","value":"$34.19"},{"label":"Consensus revenues (current fiscal year)","value":"$192.23 billion"}],"primary_claim":"Elevance Health (ELV) reported quarterly EPS of $11.97 (beating a $11.21 consensus) and revenue of $47.67B (with the article also citing a +3.68% revenue surprise) for the quarter ended March 2026.","relevance_score":0.78,"sentiment":"positive","source_quality":"high","summary":"Elevance Health (ELV) reported Q1 results that beat the Zacks Consensus Estimate for both EPS and revenue, with shares up year-to-date. The article says near-term stock direction will depend largely on management\u2019s earnings-call commentary and current earnings outlook/estimate revisions.","topics":["earnings surprise","EPS estimate","revenue estimate","earnings outlook","earnings estimate revisions","Zacks Rank","health insurance","Medical Services industry"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Elevance Health (ELV) delivered earnings and revenue surprises of +17.74% and +3.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?","tickers":["ELV"],"title":"Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates","url":"https://www.nasdaq.com/articles/elevance-health-elv-surpasses-q1-earnings-and-revenue-estimates"}... |